An interventional study of Ultrasound-Guided Microwave Ablation in Liver Metastases, Hepatic Metastases and Secondary Malignant Neoplasm of Liver, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
The liver is one of the most common organs where cancer cells spread (metastasize) from other parts of the body, especially from gastrointestinal cancers such as colorectal cancer. While surgical removal of liver tumors has traditionally been the standard treatment, most patients are not candidates for surgery due to tumor location, number of lesions, or underlying liver function. For these individuals, minimally invasive local therapies such as microwave ablation (MWA) provide an alternative approach to eradicate tumor tissue while preserving healthy liver parenchyma.
Microwave ablation delivers localized high-frequency electromagnetic energy through a thin needle antenna placed percutaneously into the liver tumor. The generated heat induces rapid coagulative necrosis, destroying cancer cells within the target area. In this study, real-time ultrasound combined with CT image-fusion navigation is used to precisely position the ablation antenna within each nodule.
The primary purpose of this study is to assess the therapeutic efficacy and safety of ultrasound-guided percutaneous microwave ablation for patients with liver metastases. Participants receive microwave ablation for their target liver tumors and are evaluated with contrast-enhanced CT or MRI at 1 month post-procedure to determine the rate of complete tumor ablation. Patients are then monitored longitudinally at 3, 6, 9, and 12 months to evaluate safety and check for local tumor recurrence.
Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants undergo percutaneous microwave ablation (MWA) targeting hepatic metastatic nodules using the MaxBlate® Microwave Ablation System (2450 MHz) with internally water-cooled antennas (15G or 16G, shaft length 100-300 mm). Needle targeting is conducted under real-time ultrasound guidance integrated with pre-acquired contrast-enhanced CT image-fusion navigation. Ablation power is calibrated between 50 W and 100 W for cycle run-times of 5 to 10 minutes based on nodule dimensions and anatomical location to achieve complete coagulative thermal necrosis.
Procedure: Ultrasound-Guided Microwave Ablation
Percutaneous thermal ablation targeting hepatic metastatic nodules using the MaxBlate® Microwave Ablation System operating at a generator frequency of 2450 MHz with internally water-cooled antennas (15G or 16G, shaft length 100-300 mm). Puncture and antenna placement are guided by real-time transabdominal ultrasound paired with pre-acquired contrast-enhanced CT image-fusion software. Thermal energy is delivered at 50 W to 100 W for 5 to 10 minutes per ablation cycle to produce coagulative necrosis encompassing the lesion and an ablative margin.
Complete Ablation Rate
Assessed via contrast-enhanced computed tomography (CECT) or gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI). Complete ablation is defined as multi-phase imaging demonstrating a distinct, non-enhancing zone of thermal necrosis that completely encompasses the margins of the target metastatic lesion. Incomplete ablation is defined as the presence of nodular, irregular, or focal contrast enhancement along the ablation margin during the arterial or portal venous phases. The outcome is reported as the percentage of targeted nodules achieving complete necrosis.
Time frame: 1 month post-procedure
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.